European expansion GenePlanet’s presence in over 35 countries and recent acquisitions (New Era Genetics) indicate a strong expansion trajectory. Sales opportunities exist in regional partnerships, distribution agreements, and co-marketing with local medical centers to accelerate market penetration.

NIPT and cancer screening leadership As a leading provider of preventive genetic tests including NIPT and cancer screening, GenePlanet can be positioned as a partner for hospitals and clinics seeking scalable, non-invasive testing solutions, enabling bundled offerings with prenatal care and oncology programs.

Healthcare ecosystem Extensive collaboration with over 1000 medical centers, doctors, and insurance companies suggests a receptive network for white-label testing, referral programs, and integrated risk assessments that can drive volume through existing payer and provider channels.

Funding and growth momentum Significant Series B funding and leadership from BlackPeak Capital, Darwin, and others reflect strong growth, prioritizing global expansion and data infrastructure. This creates opportunities to co-sell advanced analytics, big data solutions, and personalized medicine platforms.

Technology stack leverage Utilization of enterprise-grade tech (SAP, SQL, Google Analytics, data platforms) enables scalable digital marketing, CRM integration, and robust reporting. This supports targeted outreach to life sciences audiences and personalized engagement campaigns with clinics and insurance partners.